Disc Medicine Stock Alpha and Beta Analysis
| IRON Stock | 52.24 0.99 1.86% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Disc Medicine. It also helps investors analyze the systematic and unsystematic risks associated with investing in Disc Medicine over a specified time horizon. Remember, high Disc Medicine's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Disc Medicine's market risk premium analysis include:
Beta 0.81 | Alpha (0.26) | Risk 2.13 | Sharpe Ratio (0.14) | Expected Return (0.30) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Disc |
Disc Medicine Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Disc Medicine market risk premium is the additional return an investor will receive from holding Disc Medicine long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Disc Medicine. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Disc Medicine's performance over market.| α | -0.26 | β | 0.81 |
Disc Medicine expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Disc Medicine's Buy-and-hold return. Our buy-and-hold chart shows how Disc Medicine performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Disc Medicine Market Price Analysis
Market price analysis indicators help investors to evaluate how Disc Medicine stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Disc Medicine shares will generate the highest return on investment. By understating and applying Disc Medicine stock market price indicators, traders can identify Disc Medicine position entry and exit signals to maximize returns.
Disc Medicine Return and Market Media
The median price of Disc Medicine for the period between Mon, Dec 23, 2024 and Sun, Mar 23, 2025 is 55.88 with a coefficient of variation of 7.34. The daily time series for the period is distributed with a sample standard deviation of 4.22, arithmetic mean of 57.47, and mean deviation of 3.64. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 19820 shares by Quisel John D of Disc Medicine at 2.65 subject to Rule 16b-3 | 12/23/2024 |
2 | Disposition of 1900 shares by Quisel John D of Disc Medicine at 62.4107 subject to Rule 16b-3 | 12/30/2024 |
3 | Acquisition by Quisel John D of 10000 shares of Disc Medicine at 1.01 subject to Rule 16b-3 | 12/31/2024 |
4 | Disc Medicine, Inc. Shares Could Be 29 percent Below Their Intrinsic Value Estimate | 01/02/2025 |
5 | Disposition of 107 shares by White William Richard of Disc Medicine at 35.1469 subject to Rule 16b-3 | 01/06/2025 |
6 | Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria and Shares Plans for NDA Submission | 01/21/2025 |
7 | Disposition of tradable shares by White William Richard of Disc Medicine at 52.5318 subject to Rule 16b-3 | 01/24/2025 |
8 | Disposition of 1813 shares by Khara Rahul of Disc Medicine at 56.0079 subject to Rule 16b-3 | 02/03/2025 |
9 | Acquisition by Savage William Jacob of 36000 shares of Disc Medicine at 54.71 subject to Rule 16b-3 | 02/10/2025 |
10 | Disposition of 5574 shares by Quisel John D of Disc Medicine at 54.58 subject to Rule 16b-3 | 02/20/2025 |
11 | Disc Medicine Inc Announces Participation in Upcoming Investor Conferences | 02/26/2025 |
12 | Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 02/27/2025 |
13 | Decoding Disc Medicine Inc A Strategic SWOT Insight | 02/28/2025 |
14 | Wall Street Analysts Predict a 68.78 percent Upside in Disc Medicine, Inc. Heres What You Should Know | 03/03/2025 |
15 | Stocks With Rising Relative Strength Disc Medicine - Investors Business Daily | 03/06/2025 |
16 | Disposition of tradable shares by Orbimed Advisors Llc of Disc Medicine at 55.01 subject to Rule 16b-3 | 03/10/2025 |
17 | Disposition of 3567 shares by Orbimed Advisors Llc of Disc Medicine at 54.01 subject to Rule 16b-3 | 03/11/2025 |
18 | Mona Ashiya Sells 83,182 Shares of Disc Medicine, Inc. Stock | 03/14/2025 |
19 | Disposition of 5228 shares by Orbimed Advisors Llc of Disc Medicine at 54.02 subject to Rule 16b-3 | 03/19/2025 |
20 | Disposition of 364 shares by Orbimed Advisors Llc of Disc Medicine at 54.01 subject to Rule 16b-3 | 03/20/2025 |
About Disc Medicine Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Disc or other stocks. Alpha measures the amount that position in Disc Medicine has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Disc Medicine Upcoming Company Events
As portrayed in its financial statements, the presentation of Disc Medicine's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Disc Medicine's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Disc Medicine's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Disc Medicine. Please utilize our Beneish M Score to check the likelihood of Disc Medicine's management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Disc Medicine
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Disc Medicine Backtesting, Disc Medicine Valuation, Disc Medicine Correlation, Disc Medicine Hype Analysis, Disc Medicine Volatility, Disc Medicine History and analyze Disc Medicine Performance. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Disc Medicine technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.